RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032
Overview
The RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market is expected to reach a 6.11 USD Billion by 2032 and is projected to grow at a CAGR of 6.56% from 2025 to 2032.
Revenue, 2024 (USD Billion)
4.17
Forecast, 2032 (USD Billion)
6.11
CAGR, 2024 - 2032
6.56%
Report Coverage
RoMEA
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market 2018-2032 USD Billion
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 4.17 USD Billion
- Projected Market Size (2032): 6.11 USD Billion
- CAGR (2025-2032): 6.56%
Key Findings of RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market
- The RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market was valued at 4.17 USD Billion in 2024.
- The RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market is likely to grow at a CAGR of 6.56% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Whole Genome Sequencing in Test Segment accounted for the largest share of the market with a revenue of 4.74 USD Billion
- The fastest growing segment CYP2C19 in Gene Segment grew Fastest with a CAGR of 9.66% during the forecast period from 2024 to 2032.
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market Scope
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market Segmentation & Scope
Type
- Psychotic Disorders
- Eating Disorders
- Bipolar Disorders
- Mood Disorders
- Depression
- Anxiety
Patient
- Child
- Geriatric
- Adult
Gene
- COMT
- MTHFR
- SLC6A4
- CYP3A4
- HLA-A
- HTR2A/C
- Others
- HLA-B
- CYP2D6
- CYP2C9 AND VKORC1
- CYP2C19
Test
- Chromosomal Array Based Tests
- Whole Genome Sequencing
End User
- Others
- Hospital and Clinics
- Diagnostics Laboratories
- Academic And Research Institutes
Distribution Channel
- Others
- Hospital Pharmacy
- Third Party Distribution
- Direct Tender
Product
- Software and Services
- Instruments
- Consumables
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2022 |
| Unit | Revenue in USD Billion |
| Market Value in 2024 | 4.17 USD Billion |
| Market Value in 2032 | 6.11 USD Billion |
| CAGR (2025-2032) | 6.56% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Type,Patient, Gene,Test,End User,Distribution Channel,Product |
Regional Insights:
-
Leading Market (2024-2032): RoMEA, leading in terms of revenue 4.17 USD Billion in 2024
- Key Country: RoMEA, leading in terms of revenue with value of 4.17 USD Billion in 2024.
Segments and Scope
-
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Type
- Anxiety is the largest segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 1.80 USD Billion in the year 2024.
- Anxiety is the Fastest growing segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 8.67 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Patient
- Adult is the largest segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 2.52 USD Billion in the year 2024.
- Adult is the Fastest growing segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 7.63 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Gene
- CYP2C19 is the largest segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 1.34 USD Billion in the year 2024.
- CYP2C19 is the Fastest growing segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 9.66 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Test
- Whole Genome Sequencing is the largest segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 4.74 USD Billion in the year 2024.
- Whole Genome Sequencing is the Fastest growing segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 9.05 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By End User
- Hospital and Clinics is the largest segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 2.09 USD Billion in the year 2024.
- Hospital and Clinics is the Fastest growing segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 7.77 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 2.09 USD Billion in the year 2024.
- Direct Tender is the Fastest growing segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 7.66 % in forecast period 2025-2032.
-
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032, By Product
- Consumables is the largest segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a revenue of 2.16 USD Billion in the year 2024.
- Consumables is the Fastest growing segment in RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market to 2032 with a Growth rate of 8.20 % in forecast period 2025-2032.
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market Company Share Analysis
| Company Name |
|
||
| Myriad Genetics, Inc. | |||
| Illumina, Inc. | |||
| Thermo Fisher Scientific Inc. | |||
| Qiagen | |||
| Sonic Healthcare Limited | |||
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market Geographical Sales Distribution, 2018-2032 USD Billion
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Type,Patient, Gene,Test,End User,Distribution Channel,Product.
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 4.17(Revenue in USD Billion) in 2022.
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 6.56% during the forecast period of 2024 to 2032.
The Whole Genome Sequencing segment is expected to dominate the RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market, holding a largest market share of 4.74 USD Billion in 2024
Coming Soon....
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market Scope
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market Segmentation & Scope
Type
- Psychotic Disorders
- Eating Disorders
- Bipolar Disorders
- Mood Disorders
- Depression
- Anxiety
Patient
- Child
- Geriatric
- Adult
Gene
- COMT
- MTHFR
- SLC6A4
- CYP3A4
- HLA-A
- HTR2A/C
- Others
- HLA-B
- CYP2D6
- CYP2C9 AND VKORC1
- CYP2C19
Test
- Chromosomal Array Based Tests
- Whole Genome Sequencing
End User
- Others
- Hospital and Clinics
- Diagnostics Laboratories
- Academic And Research Institutes
Distribution Channel
- Others
- Hospital Pharmacy
- Third Party Distribution
- Direct Tender
Product
- Software and Services
- Instruments
- Consumables
Frequently Asked Questions
The RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Type,Patient, Gene,Test,End User,Distribution Channel,Product.
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 4.17(Revenue in USD Billion) in 2022.
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 6.56% during the forecast period of 2024 to 2032.
The estimated market value of the RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market for final year is USD 6.11 (USD Billion).
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market Company Profiling
Frequently Asked Questions
The RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market is segmented based on Segmentation Type,Patient, Gene,Test,End User,Distribution Channel,Product.
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market was valued at USD 4.17(Revenue in USD Billion) in 2022.
RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market is projected to grow at a CAGR of 6.56% during the forecast period of 2024 to 2032.
The estimated market value of the RoMEA Pharmacogenetics Testing in Psychiatry-Depression Market for final year is USD 6.11 (USD Billion).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.